Guo Zijie, Zhu Ziyu, Lin Xixi, Wang Shenkangle, Wen Yihong, Wang Linbo, Zhi Lili, Zhou Jichun
Department of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, 310016, Zhejiang, China.
Biomedical Research Center, Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, 310016, Zhejiang, China.
Biomark Res. 2024 Dec 31;12(1):166. doi: 10.1186/s40364-024-00714-6.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its high aggressiveness and poor prognosis. Conventional treatment of TNBC is challenging due to its heterogeneity and lack of clear targets. Recent advancements in immunotherapy have shown promise in treating TNBC, with immune checkpoint therapy playing a significant role in comprehensive treatment plans. The tumor microenvironment (TME), comprising immune cells, stromal cells, and various cytokines, plays a crucial role in TNBC progression and response to immunotherapy. The high presence of tumor-infiltrating lymphocytes and immune checkpoint proteins in TNBC indicates the potential of immunotherapeutic strategies. However, the complexity of the TME, while offering therapeutic targets, requires further exploration of its multiple roles in immunotherapy. In this review, we discuss the interaction mechanism between TME and TNBC immunotherapy based on the characteristics and composition of TME, and elaborate on and analyze the effect of TME on immunotherapy, the potential of TME as an immune target, and the ability of TME as a biomarker. Understanding these dynamics will offer new insights for enhancing therapeutic approaches and investigating stratification and prognostic markers for TNBC patients.
三阴性乳腺癌（TNBC）是乳腺癌的一种亚型，以其高侵袭性和不良预后而闻名。由于TNBC的异质性和缺乏明确的靶点，其传统治疗具有挑战性。免疫疗法的最新进展在治疗TNBC方面显示出前景，免疫检查点疗法在综合治疗方案中发挥着重要作用。由免疫细胞、基质细胞和各种细胞因子组成的肿瘤微环境（TME）在TNBC进展和对免疫疗法的反应中起着关键作用。TNBC中肿瘤浸润淋巴细胞和免疫检查点蛋白的高含量表明了免疫治疗策略的潜力。然而，TME的复杂性虽然提供了治疗靶点，但需要进一步探索其在免疫疗法中的多种作用。在这篇综述中，我们基于TME的特征和组成讨论了TME与TNBC免疫疗法之间的相互作用机制，并阐述和分析了TME对免疫疗法的影响、TME作为免疫靶点的潜力以及TME作为生物标志物的能力。了解这些动态将为加强治疗方法以及研究TNBC患者的分层和预后标志物提供新的见解。
